Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) Proposers' Day
ID: ARPA-H-SN-24-112Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNIH ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)Bethesda, MD, 208920004, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT (AN13)

Original Source

https://sam.gov/opp/e5a145b4c98c468189523e815b69d069/view
Timeline
    Description

    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is hosting a Proposers' Day for the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. This hybrid event, scheduled for October 1, 2024, in Nashville, Tennessee, aims to inform potential proposers about the program's objectives, which focus on advancing therapies for lymphatic health and addressing dysfunctions related to lymphatic diseases. Participants will have opportunities to engage in lightning talks, poster presentations, and networking to foster collaboration, with registration opening on July 31, 2024, and closing on September 10, 2024. Interested parties can reach out to the GLIDE Team at GLIDE@arpa-h.gov for further information.

    Point(s) of Contact
    The GLIDE Team
    GLIDE@arpa-h.gov
    Files
    Title
    Posted
    GLIDE SN - July 31 2024.pdf
    The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures (HSF) Office, is preparing to launch the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. This special notice announces an upcoming Proposers' Day on September 17, 2024, in Memphis, Tennessee, to introduce the program and encourage potential proposers to participate. The primary objective of the GLIDE program is to revolutionize the treatment of primary lymphatic diseases (LD) and common chronic diseases associated with lymphatic dysfunction. Currently, patients suffering from these conditions have limited therapeutic options, mostly palliative in nature. ARPA-H aims to develop an array of innovative treatments that address the underlying causes of lymphatic dysfunction, offering cures or, at the very least, significant relief and stabilization of the disease. The program will focus on two main areas: physical interventions to restore lymphatic flow and normalize function, and targeted pharmacologic, gene, and cell therapies. The GLIDE program seeks to make these treatments widely accessible and adoptable by the healthcare community, benefiting hospitals, doctors, and patients alike. While the special notice does not constitute a formal solicitation, it serves as an important precursor, providing potential proposers with an understanding of the program's scope and objectives, as well as offering opportunities for collaboration and team formation. The subsequent release of the Innovative Solutions Opening (ISO) will provide the full programmatic details and initiate the formal proposal submission process.
    GLIDE SN August 16 Mod.pdf
    The ARPA-H Special Notice (SN) ARPA-H-SN-24-112 details the Proposers’ Day Announcement for the groundbreaking GLIDE Program focused on lymphatic interventions and drug exploration. Scheduled for October 1, 2024, in Nashville, Tennessee, this hybrid event aims to inform potential proposers about the program's goals, scope, and collaborative opportunities. Attendance is optional but encouraged, providing a platform for networking and team formation. The GLIDE Program aims to transform treatments for lymphatic dysfunction, exploring physical interventions and therapeutics to alleviate symptoms for patients with chronic and primary lymphatic diseases. The document outlines submission guidelines for proposals, including an optional poster session and lightning talks to facilitate collaboration, as well as a "teaming profile" form for interested parties. Registration is required, opening on July 31 and closing on September 24, 2024. The notice emphasizes that participation in the Proposers’ Day is not mandatory for proposal submission and serves only as an informative and collaborative event. Additionally, attendees must register in advance, and the document clarifies the nature of this SN as an informational communication, not a solicitation for solutions. Overall, this initiative demonstrates ARPA-H's commitment to advancing equitable healthcare outcomes through innovative lymphatic research and therapies.
    GLIDE SN August 9 Mod.pdf
    The Advanced Research Projects Agency for Health (ARPA-H) is hosting a Proposers' Day for its newly approved GLIDE program. GLIDE aims to develop treatments targeting abnormal lymphatic structure and function, revolutionizing healthcare outcomes. This optional event on September 17th in Nashville, Tennessee, will provide potential proposers with program details, fostering collaborations and teaming opportunities. It will include sessions on program goals, expectations, and contracting, as well as poster and lightning talk presentations. ARPA-H encourages attendance to explore the program's mission and form teams, but participation is not mandatory for future submissions. Registration is required and will be accepted on a first-come, first-served basis. Key information and FAQs will be made available on ARPA-H's website. This Special Notice is for planning purposes only; participation is voluntary, and ARPA-H will not reimburse costs incurred.
    GLIDE SN September 23 Mod.pdf
    The Special Notice (SN) ARPA-H-SN-24-112 announces a Proposers' Day for the Advanced Research Projects Agency for Health (ARPA-H) regarding the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. Scheduled for October 1, 2024, in Nashville, Tennessee, this hybrid event aims to inform potential proposers about the program's goals and promote collaboration in advancing equitable healthcare outcomes. Registration opens on July 31, 2024, and is limited to the proposer community. GLIDE envisions significant advancements in lymphatic health, targeting abnormal lymphatic structure and function to create therapies that address underlying dysfunctions. This initiative seeks to develop both physical interventions and novel therapeutics to improve patient care for those with lymphatic diseases or related chronic conditions. Participants are encouraged to engage through optional lightning talks, poster presentations, and networking opportunities to foster collaboration. The SN details the registration process and provides a disclaimer noting that this event does not constitute a formal solicitation. Overall, the document serves to invite and prepare stakeholders for engaging with ARPA-H's innovative program aimed at enhancing healthcare systems and treatment options.
    Lifecycle
    Title
    Type
    Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) Proposers' Day
    Currently viewing
    Special Notice
    Similar Opportunities
    Industry Day - Doing Business With ARPA-H
    Active
    Health And Human Services, Department Of
    The Advanced Research Projects Agency for Health (ARPA-H), part of the Department of Health and Human Services, is hosting a virtual "Doing Business With ARPA-H" industry day event on November 13, 2024. This event aims to engage potential contractors and stakeholders in understanding ARPA-H's mission, current research and development (R&D) funding opportunities, and contracting processes, while fostering collaboration within the health ecosystem. Attendees will have the opportunity to participate in main sessions and breakout discussions, addressing various topics such as innovative solutions, teaming with small businesses, and international collaboration. Registration is mandatory by November 8, 2024, and inquiries can be directed to DBWA@arpa-h.gov. This initiative reflects ARPA-H's commitment to enhancing partnerships and maximizing health innovation through strategic collaboration.
    Ocular Laboratory for Analysis of Biomarkers (OCULAB)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is announcing a Proposers' Day for the Ocular Laboratory for Analysis of Biomarkers (OCULAB) program. This initiative aims to develop non-invasive diagnostic technologies for ocular and systemic conditions, particularly focusing on dry eye disease, through two primary technical areas: sensor technology for continuous biomarker monitoring and closed-loop therapeutic dosing systems. The Proposers' Day, scheduled for December 12, 2024, in Tampa Bay, Florida, will facilitate collaboration among participants and provide insights into the program's goals, with registration open from October 18, 2024, to December 5, 2024. Interested parties can contact OCULAB@ARPA-H.gov for further information and are encouraged to register for the event to enhance their proposal submissions.
    Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic. This initiative aims to enhance access to clinically validated curative cell therapies for pediatric patients with rare genetic diseases by advancing quality assurance mechanisms at Academic Medical Centers. The program focuses on developing innovative solutions for small-batch manufacturing of autologous cell therapies, addressing production variability, regulatory challenges, and market failures in this critical healthcare area. Proposals are due by November 18, 2024, at 12 PM EST, with the final solicitation released on October 22, 2024. Interested parties can reach out to the designated contact via the provided email for further inquiries.
    Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting innovative research proposals aimed at enhancing health outcomes via the Proactive Health Office (PHO). The initiative focuses on developing solutions that prioritize disease prevention, early intervention, and scalable wellness-promoting behaviors, moving away from traditional reactive healthcare models. This opportunity is significant for entities capable of delivering transformative health solutions, with proposals evaluated based on scientific merit and relevance, and funding potentially awarded through Other Transactions or Cooperative Agreements. Interested parties must submit a mandatory solution summary by March 3, 2029, and can direct inquiries to the designated contact via the provided submission platforms.
    Office-Wide Innovative Solutions Opening for Health Science Futures (HSF)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) aimed at advancing healthcare technologies. This initiative seeks innovative, disease-agnostic research projects that can significantly improve health outcomes, focusing on areas such as maternal and fetal health, genetic therapies, and novel diagnostic tools. The solicitation emphasizes the development of transformative solutions rather than incremental research, with submissions required to follow a two-step process: an initial solution summary followed by a full proposal based on feedback received. Interested parties must submit their solution summaries by March 3, 2029, via the designated ARPA-H portal, and are encouraged to review the detailed submission guidelines outlined in the provided documentation.
    Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting innovative solutions aimed at enhancing healthcare accessibility, affordability, and scalability. This opportunity invites universities, non-profits, small businesses, and similar entities to submit solution summaries and proposals that address health disparities, improve the distribution of healthcare technologies, and advance biomanufacturing innovations. The solicitation emphasizes the development of scalable technologies and collaborative distribution networks, with a focus on interdisciplinary approaches to revolutionize biomedicine and public health outcomes. Interested parties must submit their solution summaries by March 3, 2029, and can find further details and submission guidelines at https://solutions.arpa-h.gov. For inquiries, questions should be directed to the same website.
    A--National Gene Vector Biorepository (NGVB)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is preparing to issue a Request for Proposals (RFP) for the National Gene Vector Biorepository (NGVB) program, aimed at supporting translational gene therapy research over a five-year period. The selected contractor will be tasked with archiving over 20,000 clinical specimens under Good Laboratory Practices (GLP), developing assays for clinical testing, and maintaining a user-friendly web-based catalogue for gene therapy reagents, all while ensuring compliance with FDA regulations. This initiative underscores the government's commitment to advancing gene therapy research and enhancing the services provided by the NGVB. Interested parties should note that the RFP details are expected to be released on November 22, 2024, and can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153 for further information.
    Computational ADME Tox AnaLYsis for Safer Therapeutics (CATALYST) Innovative Solutions Opening
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is seeking innovative solutions for its Computational ADME Tox AnaLYsis for Safer Therapeutics (CATALYST) program. This initiative aims to revolutionize drug development by utilizing advanced AI and machine learning technologies to predict drug safety and efficacy, thereby reducing reliance on preclinical animal testing and improving clinical trial success rates. The program is structured in two phases, focusing on technology development and regulatory integration, with an emphasis on collaboration among universities, businesses, and product sponsors to ensure alignment with regulatory standards and enhance healthcare outcomes for diverse populations. Interested parties must submit solution summaries by November 25, 2024, at 5:00 PM ET, via the designated submission site, and can direct inquiries to the CATALYST email at CATALYST@arpa-h.gov.
    HEalth care Rewards to Achieve Improved OutcomES (HEROES)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the HEROES program, which aims to enhance public health outcomes via innovative community-based interventions. The program focuses on four critical health outcome categories: maternal health, heart attack and stroke risk, opioid overdose, and alcohol-related health harms, encouraging public health entities to develop regionally tailored, outcomes-based strategies. With a total funding amount of $99 million available over three years, multiple awards are anticipated, and proposals must demonstrate measurable impacts on health metrics within defined geographic areas. Interested parties should submit their Solution Summaries by the specified deadlines, with the full proposal due by December 10, 2024, and can direct inquiries to the ARPA-H Ask-A-Question portal.
    Agentic Artificial Intelligence (AI) for Healthcare
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is conducting a Request for Information (RFI) regarding Agentic Artificial Intelligence (AI) for healthcare. This initiative aims to gather insights on the potential applications of next-generation Agentic AI systems to enhance health outcomes, focusing on areas such as the scalability of autonomous AI agents, their interaction capabilities, interoperability, trustworthiness, performance robustness, and ethical considerations in healthcare settings. Interested parties are invited to submit their responses, limited to 10 pages, by November 29, 2024, to assist ARPA-H in shaping its research and development strategies. For further inquiries, contact Owen Hassig at owen.hassig@arpa-h.gov or Stas Blaushild at stas.blaushild@arpa-h.gov.